We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+17.45%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$587M
AUM Growth
+$91.8M
Cap. Flow
+$8.65M
Cap. Flow %
1.47%
Top 10 Hldgs %
69.79%
Holding
31
New
4
Increased
12
Reduced
11
Closed
1

Top Buys

Rank Stock Value
1
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$45.1M
2
BPMC
Blueprint Medicines
BPMC
+$13M
3
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.2M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$10.1M
5
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$9.74M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$22.4M
2
LOXO
Loxo Oncology, Inc
LOXO
+$22M
3
ARRY
Array Biopharma Inc
ARRY
+$13.7M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$7.88M
5
CCXI
ChemoCentryx, Inc.
CCXI
+$6.34M

Sector Composition

Rank Sector Weight
1 Healthcare 65.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALA
26
DELISTED
Calithera Biosciences, Inc
CALA
$1.29M 0.22%
8,395
-14,430
-63% -$2.16M
VXRT
27
DELISTED
Vaxart
VXRT
$681K 0.12%
31,889
– –
NRX
28
DELISTED
NEPHROGENEX INC COM
NRX
$627K 0.11%
+392,156
New +$911K
APTO
29
DELISTED
Aptose Biosciences, Inc.
APTO
– –
-92
Closed -$179K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2015 Portfolio in Review

As of Q4 2015, BVF Inc held 31 positions worth $587M, up 19% from $495M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc's Q4 2015 filing shows 4 new, 12 increased, 11 reduced and 1 closed positions. Its largest new stake was Alpine Immune Sciences Inc: 298,753 shares worth $9.25M. The largest sale was Ironwood Pharmaceuticals, an estimated $22.4M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 62% a quarter earlier.

  • BVF Inc's largest Q4 2015 buy was Alpine Immune Sciences Inc: 298,753 shares worth $9.25M.
  • BVF Inc added most to CTI BioPharma Corp. (DE) Common Stock in Q4 2015, an estimated $45.1M increase.
  • BVF Inc's biggest Q4 2015 reduction was Ironwood Pharmaceuticals, cutting an estimated $22.4M.
  • BVF Inc fully exited Aptose Biosciences, Inc. in Q4 2015, selling an estimated $179K.
  • BVF Inc's ten largest holdings make up 70% of its $587M portfolio in Q4 2015.
  • BVF Inc opened 4 new positions and closed 1 in Q4 2015.
  • BVF Inc's portfolio value rose 19% quarter-over-quarter to $587M.

Based on BVF Inc's 13F filing for Q4 2015, filed 16 Feb 2016.